Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07104500 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

VK2735 for Weight Management Phase 3

Study acronym: VANQUISH 1
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 137 of 137 sites
    v7
  2. Site contacts updated at 1 of 137 sitesv6
  3. Study sites: 136 to 137v5
  4. Study sites: 132 to 136v4
  5. Study sites: 121 to 132v3
  6. Study sites: 105 to 121v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Trial Details
NCT Number NCT07104500
Lead Sponsor Viking Therapeutics, Inc.
Conditions
(from sponsor)		 Weight Loss
Related terms Weight Loss
Enrollment 4,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov